Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03180840 | Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks | PHASE3 | COMPLETED | 30 | — | — | Jul 1, 2017 | Jul 1, 2020 | Sep 12, 2023 | - | — |
| Name | Type | Description |
|---|---|---|
| Pegunigalsidase alfa | BIOLOGICAL | Pegunigalsidase alfa 2 mg/kg every 4 weeks |